Thermo Fisher Scientific (TMO) EBT (2009 - 2026)

Thermo Fisher Scientific has disclosed EBT across 18 years of filings, most recently posting $1.7 billion for Q1 2026.

• Quarterly EBT rose 7.04% year-over-year to $1.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.4 billion (up 5.01% YoY) and the FY2025 annual result came in at $7.3 billion, up 3.85% from the prior year.
• EBT retreated to $1.7 billion in Q1 2026, from $2.2 billion in the prior quarter.
• Over five years, EBT peaked at $2.5 billion in Q2 2022 and troughed at $1.4 billion in Q2 2023.
• A 5-year average of $1.8 billion and a median of $1.7 billion in 2024 frame the typical range for EBT.
• Annual changes were most pronounced in 2023 — EBT plunged 46.34% — and 2024, when it advanced 23.43%.
• Tracing TMO's EBT over 5 years: stood at $1.8 billion in 2022, then dropped by 2.08% to $1.7 billion in 2023, then rose by 11.55% to $1.9 billion in 2024, then gained by 10.92% to $2.2 billion in 2025, then fell by 19.46% to $1.7 billion in 2026.
• Business Quant data shows TMO's EBT at $1.7 billion in Q1 2026, $2.2 billion in Q4 2025, and $1.8 billion in Q3 2025.